Psychiatric Times

JULY 1, 2025

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.”

Genetics and mental health 98

Genetics and mental health Bipolar disorder Sleep and mental health Aging and mental health 98

Psychiatric Times

JUNE 30, 2025

Related Videos Related Content Advertisement June 17th 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now!

Bipolar disorder 52

Bipolar disorder Genetics and mental health Sleep and mental health Aging and mental health 52

Psychiatric Times

JULY 14, 2025

Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. 2 With the potential benefits of developing lab-based diagnostic tools, there are unfortunately no definitive blood tests for bipolar disorder currently.

Bipolar disorder 52

Bipolar disorder Genetics and mental health Sleep and mental health Eating disorders 52

Psychiatric Times

JUNE 23, 2025

Overview of Attention Deficit/Hyperactivity Disorder EP: 2. Role of Pediatricians in Diagnosing ADHD ADHD risk factors encompass both genetic and environmental components that significantly impact child development. ADHD in Elementary School Age Child: Patient Case 1 EP: 3. ADHD Diagnosis Criteria EP: 4. Risk Factors for ADHD EP: 7.

Genetics and mental health 52

Genetics and mental health Bipolar disorder Nutrition and mood Sleep and mental health 52

Psychiatric Times

JUNE 30, 2025

Both medications carry important safety considerations including potential for increased suicidal ideation, requiring careful monitoring and education about distinguishing medication-related intrusive thoughts from situational mental health concerns. Subscribe Now!

Genetics and mental health 52

Genetics and mental health Bipolar disorder Neurotransmitters and mental health Sleep and mental health 52

Psychiatric Times

JUNE 23, 2025

1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.

Pharmaceuticals 95

Pharmaceuticals Bipolar disorder Genetics and mental health Manufacturing 95

Psychiatric Times

JULY 7, 2025

Together, they will aim to bring innovative mental health treatments to patients in need. Participants include 30 young adults diagnosed with BPD and 20 young adults with no mental health diagnosis, who are observed using EEG and behavioral assessments to gather objective data.

Pharmaceuticals 85

Pharmaceuticals Sleep and mental health Genetics and mental health Technology 85